切换导航
  • 比较产品
我的购物车

CryoStor® CS5

Animal component-free, defined cryopreservation medium with 5% DMSO
率先评论此产品
添加并比较

产品号 #07933_C

Animal component-free, defined cryopreservation medium with 5% DMSO

产品优势


  • Ready-to-use

  • Serum-free and protein-free

  • Animal component-free

  • cGMP manufactured with USP grade/highest-quality components

  • FDA master file

  • Sterility, endotoxin, and cell-based quality control testing

main product photo
CryoStor® CS5
概述
产品说明书及文档
应用领域
相关材料与文献

概述

Maximize post-thaw cell recovery and viability following cryopreservation at low temperatures (-80°C to -196°C) with ready-to-use CryoStor® CS5. Serum-free, animal component-free, and cGMP-manufactured, this defined medium provides a safe, protective environment for cells and tissues during freezing and thawing processes and storage. Available in a variety of convenient formats, CryoStor® CS5 is formulated with USP-grade components and contains 5% DMSO.

Contains
• 5% dimethyl sulfoxide (DMSO) <br> • Other ingredients
 
Cell Type
CHO Cells, Mesenchymal Stem and Progenitor Cells, Other, Pluripotent Stem Cells
 
Species
Human, Mouse, Non-Human Primate, Other, Rat
 
Application
Cryopreservation
 
Brand
CryoStor
 
Area of Interest
Immunology, Stem Cell Biology
 
Formulation Category
Animal Component-Free, Serum-Free
 

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
CryoStor® CS5
Catalog #
07953, 07933, 07949
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
CryoStor® CS5
Catalog #
07953, 07933, 07949
Lot #
All
Language
English

Resources and Publications

Educational Materials (10)

Hematopoietic Stem and Progenitor Cells - Products for Your Research
Brochure
Hematopoietic Stem and Progenitor Cells - Products for Your Research
Tools for Your Immunology Research
Brochure
Tools for Your Immunology Research
Products for Human Pluripotent Stem Cells
Brochure
Products for Human Pluripotent Stem Cells
T Cell Reagents for Your Cellular Therapy Research
Brochure
T Cell Reagents for Your Cellular Therapy Research
hPSC Differentiation: Tools for Pluripotent Stem Cell-Derived Research
Brochure
hPSC Differentiation: Tools for Pluripotent Stem Cell-Derived Research
Cryopreservation Media for Stem Cell Research
Brochure
Cryopreservation Media for Stem Cell Research
Frequencies of Human Cell Types in Blood-Related Sources
Wallchart
Frequencies of Human Cell Types in Blood-Related Sources
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Directed Differentiation of Pluripotent Stem Cells
Wallchart
Directed Differentiation of Pluripotent Stem Cells
Human T Cell Expansion Course
On-Demand Training
Human T Cell Expansion Course

Publications (9)

Inflammatory Responses and Barrier Function of Endothelial Cells Derived from Human Induced Pluripotent Stem Cells. O. V. Halaidych et al. Stem cell reports 2018 MAY

Abstract

Several studies have reported endothelial cell (EC) derivation from human induced pluripotent stem cells (hiPSCs). However, few have explored their functional properties in depth with respect to line-to-line and batch-to-batch variability and how they relate to primary ECs. We therefore carried out accurate characterization of hiPSC-derived ECs (hiPSC-ECs) from multiple (non-integrating) hiPSC lines and compared them with primary ECs in various functional assays, which included barrier function using real-time impedance spectroscopy with an integrated assay of electric wound healing, endothelia-leukocyte interaction under physiological flow to mimic inflammation and angiogenic responses in in vitro and in vivo assays. Overall, we found many similarities but also some important differences between hiPSC-derived and primary ECs. Assessment of vasculogenic responses in vivo showed little difference between primary ECs and hiPSC-ECs with regard to functional blood vessel formation, which may be important in future regenerative medicine applications requiring vascularization.
View publication
Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. S. J. Priceman et al. Oncoimmunology 2018

Abstract

Advancing chimeric antigen receptor (CAR)-engineered adoptive T cells for the treatment of solid cancers is a major focus in the field of immunotherapy, given impressive recent clinical responses in hematological malignancies. Prostate cancer may be amenable to T cell-based immunotherapy since several tumor antigens, including prostate stem-cell antigen (PSCA), are widely over-expressed in metastatic disease. While antigen selectivity of CARs for solid cancers is crucial, it is problematic due to the absence of truly restricted tumor antigen expression and potential safety concerns with on-target off-tumor" activity. Here
View publication
SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes. M. D. Lacher et al. Frontiers in immunology 2018

Abstract

Targeted cancer immunotherapy with irradiated, granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting, allogeneic cancer cell lines has been an effective approach to reduce tumor burden in several patients. It is generally assumed that to be effective, these cell lines need to express immunogenic antigens coexpressed in patient tumor cells, and antigen-presenting cells need to take up such antigens then present them to patient T cells. We have previously reported that, in a phase I pilot study (ClinicalTrials.gov NCT00095862), a subject with stage IV breast cancer experienced substantial regression of breast, lung, and brain lesions following inoculation with clinical formulations of SV-BR-1-GM, a GM-CSF-secreting breast tumor cell line. To identify diagnostic features permitting the prospective identification of patients likely to benefit from SV-BR-1-GM, we conducted a molecular analysis of the SV-BR-1-GM cell line and of patient-derived blood, as well as a tumor specimen. Compared to normal human breast cells, SV-BR-1-GM cells overexpress genes encoding tumor-associated antigens (TAAs) such as PRAME, a cancer/testis antigen. Curiously, despite its presumptive breast epithelial origin, the cell line expresses major histocompatibility complex (MHC) class II genes (HLA-DRA, HLA-DRB3, HLA-DMA, HLA-DMB), in addition to several other factors known to play immunostimulatory roles. These factors include MHC class I components (B2M, HLA-A, HLA-B), ADA (encoding adenosine deaminase), ADGRE5 (CD97), CD58 (LFA3), CD74 (encoding invariant chain and CLIP), CD83, CXCL8 (IL8), CXCL16, HLA-F, IL6, IL18, and KITLG. Moreover, both SV-BR-1-GM cells and the responding study subject carried an HLA-DRB3*02:02 allele, raising the question of whether SV-BR-1-GM cells can directly present endogenous antigens to T cells, thereby inducing a tumor-directed immune response. In support of this, SV-BR-1-GM cells (which also carry the HLA-DRB3*01:01 allele) treated with yellow fever virus (YFV) envelope (Env) 43-59 peptides reactivated YFV-DRB3*01:01-specific CD4+ T cells. Thus, the partial HLA allele match between SV-BR-1-GM and the clinical responder might have enabled patient T lymphocytes to directly recognize SV-BR-1-GM TAAs as presented on SV-BR-1-GM MHCs. Taken together, our findings are consistent with a potentially unique mechanism of action by which SV-BR-1-GM cells can act as APCs for previously primed CD4+ T cells.
View publication
View All Publications
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。